Lehnert T, Deschner E E, Karmali R A, DeCosse J J
J Natl Cancer Inst. 1987 May;78(5):923-9.
The effect of exogenous synthetic prostaglandins and the inhibition of endogenous prostaglandin synthesis on gastrointestinal tumorigenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine [(MNNG) CAS: 70-25-7] was studied in female Wistar rats (100 g). Animals were divided into 6 groups: Group I was treated with MNNG alone (No. = 43); group II was treated with MNNG after application of the cyclo-oxygenase inhibitor flurbiprofen (No. = 44); group III was treated with MNNG after oral administration of 16,16-dimethyl-prostaglandin E2 (16,16-dm-PGE2; No. = 43); group IV received flurbiprofen alone (No. = 15); group V was treated with 16,16-dm-PGE2 alone (No. = 11). Animals in group VI served as controls (No. = 15). All drugs were administered orally. Hyperkeratosis and hyperplasia of the forestomach developed by 10 days after the first treatment with the carcinogen. Later, benign papillomas and dysplastic lesions were noted. Progressive ingrowth of squamous epithelium from the forestomach ridge into the glandular stomach started as early as day 13 and was more frequent in animals treated with a combination of MNNG plus flurbiprofen (P less than .001). The first squamous cell carcinomas of the forestomach were detected on day 51. Their incidence was 38, 60, and 42% in groups I, II, and III, respectively. This difference was not statistically significant. The incidence of mesenchymal tumors (leiomyosarcoma) in the stomach and duodenum was higher following treatment with MNNG plus flurbiprofen as compared to the incidence following treatment with MNNG alone or in combination with 16,16-dm-PGE2 (P less than .005). No malignant tumors developed in the gastrointestinal tracts of animals treated with flurbiprofen or 16,16-dm-PGE2 alone or in controls. The higher incidence of gastric and duodenal leiomyosarcomas after treatment with flurbiprofen suggests that reduction of prostaglandin synthesis favored the development of MNNG-induced cancer in mesenchymal tissues of the upper gastrointestinal tract.
在100克雌性Wistar大鼠中研究了外源性合成前列腺素以及内源性前列腺素合成抑制对N-甲基-N'-硝基-N-亚硝基胍[(MNNG),CAS:70-25-7]诱导的胃肠道肿瘤发生的影响。动物分为6组:第I组仅用MNNG处理(n = 43);第II组在应用环氧化酶抑制剂氟比洛芬后用MNNG处理(n = 44);第III组在口服16,16-二甲基前列腺素E2(16,16-dm-PGE2)后用MNNG处理(n = 43);第IV组仅接受氟比洛芬(n = 15);第V组仅用16,16-dm-PGE2处理(n = 11)。第VI组动物作为对照(n = 15)。所有药物均经口服给药。在首次用致癌物处理后10天,前胃出现角化过度和增生。随后,发现了良性乳头状瘤和发育异常病变。前胃嵴的鳞状上皮向腺胃的渐进性内生早在第13天就开始了,并且在MNNG加氟比洛芬联合处理的动物中更常见(P<0.001)。在第51天检测到前胃的首例鳞状细胞癌。它们在第I、II和III组中的发生率分别为38%、60%和42%。这种差异无统计学意义。与单独用MNNG处理或与16,16-dm-PGE2联合处理相比,MNNG加氟比洛芬处理后胃和十二指肠间质瘤(平滑肌肉瘤)的发生率更高(P<0.005)。单独用氟比洛芬或16,16-dm-PGE2处理的动物或对照组动物的胃肠道未发生恶性肿瘤。氟比洛芬处理后胃和十二指肠平滑肌肉瘤的较高发生率表明,前列腺素合成的减少有利于MNNG诱导的上消化道间质组织癌症的发展。